Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Zabernigg, August ^a   Giesinger, Johannes M ^b   Pall, Georg ^c   Gamper, Eva Maria ^b   Gattringer, Klaus ^a   Wintner, Lisa M ^b,d   Sztankay, Monika J ^b,d   Holzner, Bernhard ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cancer of biliary tract; Chemotherapy; Electronic patient reported outcome monitoring; Quality of life, Pancreatic cancer

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

AGED; ARTICLE; BILIARY TRACT CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PANCREAS CANCER; PATIENT ASSESSMENT; PATIENT MONITORING; QUALITY OF LIFE; SELF REPORT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84865737012     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-390     Document Type: Article

References (32)

1. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996, 7(6):593-600. 10.1093/oxfordjournals.annonc.a010676, 8879373.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-13.T.
3. Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008, 26(22):3702-8. 10.1200/JCO.2008.16.5704, 18669455.
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-25. 10.1056/NEJMoa1011923, 21561347.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-6. 10.1200/JCO.2006.07.9525, 17452677.
6. Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 2012, 43(2):205-17. 10.1016/j.jpainsymman.2011.09.001, 22104618.
7. Moinpour CM, Vaught NL, Goldman B, et al. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol 2010, 28(22):3611-6. 10.1200/JCO.2009.25.8285, 2917316, 20606094.
8. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28(10):1645-51. 10.1200/JCO.2009.25.4433, 20194854.
9. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27(33):5513-8. 10.1200/JCO.2009.24.2446, 19858379.
10. Bernhard J, Dietrich D, Scheithauer W, et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 2008, 26(22):3695-701.
11. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362(14):1273-81. 10.1056/NEJMoa0908721, 20375404.
12. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011, 47(11):1676-81. 10.1016/j.ejca.2011.04.011, 21565490.
13. Lee S, Oh SY, Kim BG, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009, 32(4):348-52. 10.1097/COC.0b013e31818c08ff, 19363436.
14. Bonnetain F, Dahan L, Maillard E, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer 2010, 46(15):2753-62. 10.1016/j.ejca.2010.07.023, 20724140.
15. Dahan L, Bonnetain F, Ychou M, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010, 59(11):1527-34. 10.1136/gut.2010.216135, 2981019, 20947887.
16. Katopodis O, Polyzos A, Kentepozidis N, et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011, 67(2):361-8. 10.1007/s00280-010-1329-6, 20428874.
17. Carter R, Stocken DD, Ghaneh P, et al. Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer 2009, 124(12):2960-5. 10.1002/ijc.24270, 19330830.
18. Eckhardt SG, De Porre P, Smith D, et al. Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J Pain Symptom Manage 2009, 37(2):135-43. 10.1016/j.jpainsymman.2008.02.007, 2856704, 18723314.
19. ESD Inc., E.S.D Computer-Based Health Evaluation System (CHES) 2011, Innsbruck, Austria, ESD Inc., E.S.D.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-76. 10.1093/jnci/85.5.365, 8433390.
21. Zabernigg A, Gamper EM, Giesinger JM, et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect?. Oncologist 2010, 15(8):913-20. 10.1634/theoncologist.2009-0333, 3228016, 20667968.
22. Gamper EM, Giesinger JM, Oberguggenberger A, et al. Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: Prevalence, course of severity, and quality of life correlates. Acta Oncol 2011,
23. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16(1):139-44.
24. Crippa S, Dominguez I, Rodriguez JR, et al. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 2008, 12(5):783-93. discussion 793-4, 10.1007/s11605-007-0391-9, 18317851.
25. Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009, 101(10):1658-63. 10.1038/sj.bjc.6605374, 2778540, 19826418.
26. Temel JS, Greer JA, Admane S, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol 2011, 29(17):2319-26. 10.1200/JCO.2010.32.4459, 21555700.
27. Aarts MJ, Lemmens VE, Louwman MW, Kunst AE, Coebergh JW. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer 2010, 46(15):2681-95. 10.1016/j.ejca.2010.04.026, 20570136.
28. Cavalli-Bjorkman N, Lambe M, Eaker S, Sandin F, Glimelius B. Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer 2011, 47(9):1398-406. 10.1016/j.ejca.2010.12.013, 21237637.
29. Lutgendorf SK, De Geest K, Bender D, et al. Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol 2012, 30(23):2885-90. 10.1200/JCO.2011.39.4411, 22802321.
30. Cavalli-Björkman N, Qvortrup C, Sebjornsen S, et al. Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. Br J Cancer 2012, 107(1):189-94. 10.1038/bjc.2012.186, 22576591.
31. May AM, Duivenvoorden HJ, Korstjens I, et al. The effect of group cohesion on rehabilitation outcome in cancer survivors. Psychooncology 2008, 17(9):917-25. 10.1002/pon.1308, 18095262.
32. Rottmann N, Dalton SO, Bidstrup PE, et al. No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial. Psychooncology 2012, 21(5):505-14.